Galectin Therapeutics Inc (GALT)

• $2.71

  $2.97

  $2.72
  

  0.37%

  Downside

  Day's Volatility :8.6%

  Upside

  8.26%

  
• $1.56

  $4.27

  $2.72
  

  42.83%

  Downside

  52 Weeks Volatility :63.57%

  Upside

  36.28%

  

Returns

What analysts predicted

Upside of 304.41%

• Vanguard Group Inc

  3.40%

• BlackRock Inc

  2.51%

• Advisor Group Holdings, Inc.

  1.81%

• Geode Capital Management, LLC

  1.35%

• Commonwealth Equity Services Inc

  0.78%

• Sontag Advisory LLC

  0.64%

galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much